Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Publikationen

Suchbegriffe: 5-FLUOROURACIL, . Treffer: 52

2023

Kesic, V; Carcopino, X; Preti, M; Vieira-Baptista, P; Bevilacqua, F; Bornstein, J; Chargari, C; Cruickshank, M; Erzeneoglu, E; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kyrgiou, M; Madić, T; Planchamp, F; Regauer, S; Reich, O; Esat, Temiz, B; Woelber, L; Zodzika, J; Stockdale, C The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus statement on the management of vaginal intraepithelial neoplasia.
Int J Gynecol Cancer. 2023; 33(4):446-461 Doi: 10.1136/ijgc-2022-004213 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Kesic, V; Carcopino, X; Preti, M; Vieira-Baptista, P; Bevilacqua, F; Bornstein, J; Chargari, C; Cruickshank, M; Erzeneoglu, E; Gallio, N; Gultekin, M; Heller, D; Joura, E; Kyrgiou, M; Madić, T; Planchamp, F; Regauer, S; Reich, O; Esat, Temiz, B; Woelber, L; Zodzika, J; Stockdale, C The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) Consensus Statement on the Management of Vaginal Intraepithelial Neoplasia.
J Low Genit Tract Dis. 2023; 27(2):131-145 Doi: 10.1097/LGT.0000000000000732 [OPEN ACCESS]
PubMed FullText FullText_MUG

2021

Keil, M; Conrad, T; Becker, M; Keilholz, U; Yaspo, ML; Lehrach, H; Schütte, M; Haybaeck, J; Hoffmann, J Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data.
Cancers (Basel). 2021; 13(23): Doi: 10.3390/cancers13236018 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2019

Maneikyte, J; Bausys, A; Leber, B; Horvath, A; Feldbacher, N; Hoefler, G; Strupas, K; Stiegler, P; Schemmer, P Dietary glycine decreases both tumor volume and vascularization in a combined colorectal liver metastasis and chemotherapy model.
Int J Biol Sci. 2019; 15(8):1582-1590 Doi: 10.7150/ijbs.35513 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2017

Dirschka, T; Gupta, G; Micali, G; Stockfleth, E; Basset-Séguin, N; Del Marmol, V; Dummer, R; Jemec, GBE; Malvehy, J; Peris, K; Puig, S; Stratigos, AJ; Zalaudek, I; Pellacani, G Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology.
J Dermatolog Treat. 2017; 28(5):431-442 Doi: 10.1080/09546634.2016.1254328 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Kafka, M; Collins, V; Kamolz, LP; Rappl, T; Branski, LK; Wurzer, P Evidence of invasive and noninvasive treatment modalities for hypertrophic scars: A systematic review.
Wound Repair Regen. 2017; 25(1):139-144 Doi: 10.1111/wrr.12507
Web of Science PubMed FullText FullText_MUG

Schramm, A; Schochter, F; Friedl, TWP; de Gregorio, N; Andergassen, U; Alunni-Fabbroni, M; Trapp, E; Jaeger, B; Heinrich, G; Camara, O; Decker, T; Ober, A; Mahner, S; Fehm, TN; Pantel, K; Fasching, PA; Schneeweiss, A; Janni, W; Rack, BK; SUCCESS Study Group Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Clin Breast Cancer. 2017; 17(4):279-285 Doi: 10.1016/j.clbc.2016.11.008
Web of Science PubMed FullText FullText_MUG

2015

Bohanes, P; Yang, D; Loupakis, F; LaBonte, MJ; Gerger, A; Ning, Y; Lenz, C; Lenz, F; Wakatsuki, T; Zhang, W; Benhaim, L; El-Khoueiry, A; El-Khoueiry, R; Lenz, HJ Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Pharmacogenomics J. 2015; 15(3):226-234 Doi: 10.1038/tpj.2014.66
Web of Science PubMed FullText FullText_MUG

Haymerle, G; Thurnher, D; Kadletz, L; Stanisz, I; Brunner, M; Kotowski, U; Enzenhofer, E; Heiduschka, G Assessment of caroverine as a potential chemotherapeutical agent in HNSCC cell lines.
Eur Arch Otorhinolaryngol. 2015; 272(11):3451-3456 Doi: 10.1007/s00405-014-3364-0
Web of Science PubMed FullText FullText_MUG

Kandioler, D; Mittlböck, M; Kappel, S; Puhalla, H; Herbst, F; Langner, C; Wolf, B; Tschmelitsch, J; Schippinger, W; Steger, G; Hofbauer, F; Samonigg, H; Gnant, M; Teleky, B; Kührer, I; p53 Research Group and the Austrian Breast and Colorectal Study Group (ABCSG) TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
EBioMedicine. 2015; 2(8):825-830 Doi: 10.1016/j.ebiom.2015.06.003 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Smolle, MA; Pichler, M; Haybaeck, J; Gerger, A Genetic markers of recurrence in colorectal cancer.
Pharmacogenomics. 2015; 16(11):1315-1328 Doi: 10.2217/pgs.15.83
Web of Science PubMed FullText FullText_MUG

Szkandera, J; Herzog, S; Pichler, M; Stiegelbauer, V; Stotz, M; Schaberl-Moser, R; Samonigg, H; Asslaber, M; Lax, S; Leitner, G; Renner, W; Lenz, HJ; Berghold, A; Gerger, A LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
Pharmacogenomics J. 2015; 15(5):391-396 Doi: 10.1038/tpj.2015.2 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2014

Absenger, G; Benhaim, L; Szkandera, J; Zhang, W; Yang, D; Labonte, MJ; Pichler, M; Stotz, M; Samonigg, H; Renner, W; Gerger, A; Lenz, HJ The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.
Pharmacogenomics J. 2014; 14(2):130-134 Doi: 10.1038/tpj.2013.15
Web of Science PubMed FullText FullText_MUG Google Scholar

Heitzer, E; Artl, M; Filipits, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Höfler, G; Samonigg, H; Schaberl-Moser, R; Balic, M; Dandachi, N Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Mod Pathol. 2014; 27(6):906-915 Doi: 10.1038/modpathol.2013.204 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Páez, D; Gerger, A; Zhang, W; Yang, D; Labonte, MJ; Benhanim, L; Kahn, M; Lenz, F; Lenz, C; Ning, Y; Wakatsuki, T; Loupakis, F; Lenz, HJ Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
Pharmacogenomics J. 2014; 14(2):142-150 Doi: 10.1038/tpj.2013.20
Web of Science PubMed FullText FullText_MUG

Stiegelbauer, V; Perakis, S; Deutsch, A; Ling, H; Gerger, A; Pichler, M MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
World J Gastroenterol. 2014; 20(33):11727-11735 Doi: 10.3748/wjg.v20.i33.11727 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Szkandera, J; Pichler, M; Absenger, G; Stotz, M; Weissmueller, M; Samonigg, H; Asslaber, M; Lax, S; Leitner, G; Winder, T; Renner, W; Gerger, A A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
Clin Cancer Res. 2014; 20(6):1687-1697 Doi: 10.1158/1078-0432.CCR-13-1517 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2011

Brunner, TB; Sauer, R; Fietkau, R Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Radiat Oncol. 2011; 6:88 Doi: 10.1186/1748-717X-6-88 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Stockfleth, E; Kerl, H; Zwingers, T; Willers, C Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.
BRIT J DERMATOL. 2011; 165(5): 1101-1108. Doi: 10.1111/j.1365-2133.2011.10387.x
Web of Science PubMed FullText FullText_MUG

2010

Idris, T; Krippl, P; Lang, U; Petru, E Long-Term Disease Control with Lapatinib and Capecitabine in a Heavily Pretreated Patient with ErbB2-Positive Metastatic Breast Cancer.
Breast Care (Basel). 2010; 5(5):335-337 Doi: 10.1159/000321394 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

2008

Brunner, TB; Rupp, A; Melzner, W; Grabenbauer, GG; Sauer, R Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
Strahlenther Onkol. 2008; 184(1):15-22 Doi: 10.1007/s00066-008-1787-5
Web of Science PubMed FullText FullText_MUG

Dubsky, P; Sevelda, P; Jakesz, R; Hausmaninger, H; Samonigg, H; Seifert, M; Denison, U; Mlineritsch, B; Steger, G; Kwasny, W; Stöger, H; Bartsch, R; Stierer, M; Taucher, S; Fridrik, M; Schippinger, W; Greil, R; Pötter, R; Gnant, M; Austrian Breast and Colorectal Cancer Study Group Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Clin Cancer Res. 2008; 14(7):2082-2087 Doi: 10.1158/1078-0432.CCR-07-2068 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Petru, E; Andel, J; Angleitner-Boubenizek, L; Steger, G; Bernhart, M; Busch, K; Gehmacher, O; Hernler, T; Kastner, U; Lanz-Veit, A; Pluschnigg, U; Polachova, J; Rohde, M; Schiller, L; Schramböck, R; Stangl, W; Thödtmann, R; Zabernigg, A Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Wien Med Wochenschr. 2008; 158(5-6): 169-173. Doi: 10.1007/s10354-008-0515-1
PubMed FullText FullText_MUG Google Scholar

Skoda, C; Erovic, BM; Wachek, V; Vormittag, L; Wrba, F; Martinek, H; Heiduschka, G; Kloimstein, P; Selzer, E; Thurnher, D Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Oncol Rep. 2008; 19(6):1499-1503
Web of Science PubMed

Weger, W; Kränke, B; Gerger, A; Salmhofer, W; Aberer, E Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine.
J Am Acad Dermatol. 2008; 59(2 Suppl 1):S4-S6 Doi: 10.1016/j.jaad.2007.06.040 (- Case Report)
Web of Science PubMed FullText FullText_MUG

2002

Eckel, F; Schmelz, R; Adelsberger, H; Erdmann, J; Quasthoff, S; Lersch, C Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study
DEUT MED WOCHENSCHR 2002 127: 78-82. Doi: 10.1055/s-2002-19594
Web of Science PubMed FullText FullText_MUG

Jakesz, R; Hausmaninger, H; Samonigg, H Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.
Eur J Cancer. 2002; 38(3):327-332 Doi: 10.1016%2FS0959-8049%2801%2900375-6
Web of Science PubMed FullText FullText_MUG Google Scholar

2001

Kapp, KS; Geyer, E; Gebhart, FH; Oechs, AC; Berger, A; Hebenstreit, J; Stoeger, H Experience with split-course external beam irradiation +/- chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal.
Int J Radiat Oncol Biol Phys. 2001; 49(4):997-1005 Doi: 10.1016/s0360-3016(00)01427-9
Web of Science PubMed FullText FullText_MUG

Nauck, M; Gierens, H; März, W; Wieland, H Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes.
Clin Biochem. 2001; 34(2):103-105 Doi: 10.1016/S0009-9120(01)00188-6
Web of Science PubMed FullText FullText_MUG Google Scholar

2000

Brunner, TB; Grabenbauer, GG; Kastl, S; Herrmann, O; Baum, U; Fietkau, R; Klein, P; Bautz, W; Schneider, T; Hohenberger, W; Sauer, R Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study.
Onkologie. 2000; 23(5):436-442 Doi: 10.1159/000027214
Web of Science PubMed FullText FullText_MUG

Kastl, S; Brunner, T; Herrmann, O; Riepl, M; Fietkau, R; Grabenbauer, G; Sauer, R; Hohenberger, W; Klein, P Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas.
Eur J Surg Oncol. 2000; 26(6):578-82 Doi: 10.1053/ejso.2000.0950
Web of Science PubMed FullText FullText_MUG

1999

Gmeinhart, B; Hinterberger, W; Greinix, HT; Rabitsch, W; Kirnbauer, R; Reiter, E; Volc-Platzer, B Anaplastic squamous cell carcinoma (SCC) in a patient with chronic cutaneous graft-versus-host disease (GVHD).
Bone Marrow Transplant. 1999; 23(11):1197-1199 Doi: 10.1038/sj.bmt.1701772 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Hausmaninger, H; Moser, R; Samonigg, H; Mlineritsch, B; Schmidt, H; Pecherstorfer, M; Fridrik, M; Kopf, C; Nitsche, D; Kaider, A; Ludwig, H Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Eur J Cancer. 1999; 35(3):380-385 Doi: 10.1016%2FS0959-8049%2898%2900397-9
Web of Science PubMed FullText FullText_MUG Google Scholar

1998

Grabenbauer, GG; Steininger, H; Meyer, M; Fietkau, R; Brunner, T; Heinkelmann, P; Hornung, J; Iro, H; Spitzer, W; Kirchner, T; Sauer, R; Distel, L Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer.
Radiother Oncol. 1998; 47(2):175-83 Doi: 10.1016/s0167-8140(98)00016-4
Web of Science PubMed FullText FullText_MUG

1995

Moser, R; Hausmaninger, H; Ludwig, H; Fridrik, M; Schmidt, H; Mlineritsch, B; Pecherstorfer, M; Michlmayr, G; Kopf, C; Samonigg, H 5-Fluorouracil and Folinic Acid with or Without Alpha-2C Interferon in the Treatment of Metastatic Colorectal-Cancer - Preliminary-Results of a Multicenter Prospective Randomized Phase-III Trial
ONKOLOGIE 1995 18: 131-135. Doi: 10.1159/000218573
Web of Science FullText FullText_MUG

Petru, E; Haas, J; Schaider, H; Sevin, BU Do cell cycle changes of human ovarian carcinoma cells after exposure to cytostatic drugs in vitro correlate with cytotoxicity?
GYNAKOL GEBURTSHILFL RUNDSCH. 1995; 35 Suppl 1: 15-18. Doi: 10.1159/000272557
Web of Science PubMed FullText FullText_MUG

Petru, E; Sevin, BU; Haas, J; Ramos, R; Perras, J A correlation of cell cycle perturbations with chemosensitivity in human ovarian cancer cells exposed to cytotoxic drugs in vitro.
Gynecol Oncol. 1995; 58(1):48-57 Doi: 10.1006/gyno.1995.1182
Web of Science PubMed FullText FullText_MUG Google Scholar

Trauner, M; Klimpfinger, M; Stauber, RE; Schreiber, F; Stöger, H; Krejs, GJ Laparoscopic diagnosis of peritoneal serous papillary carcinoma.
Endoscopy. 1995; 27(4):337-341 Doi: 10.1055/s-2007-1005704 (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar

1994

Kapp, KS; Kapp, DS; Stuecklschweiger, G; Berger, A; Geyer, E Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
Int J Radiat Oncol Biol Phys. 1994; 28(1):189-199 Doi: 10.1016/0360-3016(94)90157-0
Web of Science PubMed FullText FullText_MUG

Stöger, H; Bauernhofer, T; Kasparek, AK; Schmid, M; Moser, R; Ploner, F; Derstvenscheg, E; Kuss, I; Wilders-Truschnig, M; Steindorfer, P Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.
Cancer Chemother Pharmacol. 1994; 34(1):75-78 Doi: 10.1007/BF00686116
Web of Science PubMed FullText FullText_MUG

Stöger, H; Bauernhofer, T; Schmid, M; Ploner, F; Moser, R; Derstvenscheg, E; Steindorfer, P; Wilders-Truschnig, M; Kuss, I; Samonigg, H A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Cancer Chemother Pharmacol. 1994; 35(2):174-178 Doi: 10.1007/BF00686643
Web of Science PubMed FullText FullText_MUG

Stöger, H; Schmid, M; Bauernhofer, T; Moser, R; Ploner, F; Derstvenscheg, E; Kasparek, AK; Kuss, I; Wilders-Truschnig, M; Lackner, C A phase II trial of weekly high-dose folinic acid and 5-fluorouracil in combination with epirubicin as salvage chemotherapy in advanced breast cancer.
Oncology. 1994; 51(6):518-522 Doi: 10.1159/000227397
Web of Science PubMed FullText FullText_MUG Google Scholar

Zimmermann, T; Schemmer, P; Berghäuser, KH; Mylo, M; Buhr, J; Padberg, WM Interactions between malignant tumor growth and allogeneic graft rejection in an experimental rat model.
Transpl Int. 1994; 7 Suppl 1(1-2):S618-S620 Doi: 10.1111/j.1432-2277.1994.tb01457.x
PubMed FullText FullText_MUG

1991

Petru, E; Schmähl, D Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
Neoplasma. 1991; 38(2):147-155
Web of Science PubMed Google Scholar

Samonigg, H; Stöger, H; Kasparek, AK; Schmid, M; Dusleag, J; Pfeiffer, K; Smola, M; Steindorfer, P; Lechner, P Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Cancer Chemother Pharmacol. 1991; 27(6):477-480 Doi: 10.1007/BF00685163
Web of Science PubMed FullText FullText_MUG Google Scholar

1990

Samonigg, H; Stöger, H; Bauernhofer, T; Schmid, M; Kasparek, AK; Kuss, I; Kaul, M; Heberle, U; Vieder, L; Dusleag, J Combination therapy of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose folinic acid in patients with advanced breast cancer: a phase I-II study (preliminary results).
Am J Clin Oncol. 1990; 13 Suppl 1(4):S44-S47 Doi: 10.1097/00000421-199012001-00010
Web of Science PubMed FullText FullText_MUG Google Scholar

1989

Auner, H; Petru, E; Hofmann, HM; Pickel, H; Pürstner, P In vitro chemosensitivity testing in the treatment of ovarian carcinoma.
Arch Gynecol Obstet. 1989; 246(4):227-231 Doi: 10.1007/BF00934523
Web of Science PubMed FullText FullText_MUG Google Scholar

Weitere 50 Treffer anzeigen

↑ Seitenanfang / Navigation